News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Insert Therapeutics Inc. Signs New Partnership with R&D-Biopharmaceuticals GmbH


3/1/2007 12:31:05 PM

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ:ARWR) announced today that Insert Therapeutics, its majority-owned subsidiary, signed a definitive agreement with R&D Biopharmaceuticals in which it will acquire an exclusive, world-wide license to multiple second generation epothilone anticancer drugs. Insert will apply its proprietary Cyclosert transport system to select second generation epothilones now in development at R&D.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES